RecruitingPHASE1, PHASE2NCT06185764

A Phase 1/2 Study of VX-670 in Adult Participants With Myotonic Dystrophy 1 (DM1)

Studying Steinert myotonic dystrophy

Last synced from ClinicalTrials.gov May 7, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Vertex Pharmaceuticals Incorporated
Intervention: VX-670(drug)
Enrollment: 44 enrolled
Eligibility: 18-64 years · All sexes
Timeline: 2024 – 2026

Study locations (26)

Stanford Neuromuscular Research, San Carlos, California, United States
University of Florida Clinical Research Center, Gainesville, Florida, United States
University of Kansas Medical Center, Fairway, Kansas, United States
Boston Children's Hospital, Boston, Massachusetts, United States
Washington University School of Medicine / St. Louis Children's Hospital, St Louis, Missouri, United States
Wake Forest Baptist Health, Winston-Salem, North Carolina, United States
University of Pennsylvania, Philadelphia, Pennsylvania, United States
Virginia Commonwealth University (Sanger Hall), Richmond, Virginia, United States
Wesley Research Institute, Auchenflower, Australia
Neuroscience Clinical Trials Unit, Alfred Brain, Melbourne, Australia
Universitaire Ziekenhuizen Leuven - Campus Gasthuisberg, Leuven, Belgium
Hopital de Chicoutimi, Chicoutimi, Canada
Altasciences Montreal, Montreal, Canada
McGIll University, Montreal, Canada
University of Ottawa, Ottawa, Canada
+11 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06185764 on ClinicalTrials.gov

Other trials for Steinert myotonic dystrophy

Additional recruiting or active studies for the same condition.

See all trials for Steinert myotonic dystrophy →

← Back to all trials